Thursday, October 22, 2020
Home Latest Pharma-News UK inks deal with Abingdon Health for rapid COVID-19 antibody tests

UK inks deal with Abingdon Health for rapid COVID-19 antibody tests

October 7, 2020: “The UK authorities has introduced a deal with Abingdon Health for the provision of the corporate’s AbC-19 rapid COVID-19 antibody tests.

The contract features a first order for a million AbC-19 tests, with the tests set to be rolled out underneath the federal government’s COVID-19 surveillance research.

- Advertisement -

The purpose of those research is to realize a transparent image of how the virus has unfold throughout the nation, and develop understanding of how antibodies work.

It may even be capable of assist decide the efficacy of any vaccine at present in improvement, which offer safety by creating new antibodies in opposition to COVID-19.

Abingdon’s antibody check makes use of a small drop of blood from a person by a finger-prick, and reveals outcomes inside 20 minutes with out the necessity to go to a specialised laboratory.

The check detects IgG antibodies to full trimeric spike proteins of the SARS-CoV-2 virus, which causes COVID-19.

This means Abingdon’s check detects antibodies which intervene with the virus’s skill to enter the human cells.

The AbC-19 check has already acquired a CE mark, which implies it conforms to well being and security requirements for items offered within the UK and EU.

The check has additionally undergone an impartial analysis, commissioned by the UK authorities, which is about to be revealed in the end by Public Health England after a peer assessment.

“Our test will help give a picture of how many people in the UK have antibodies.  This will be a crucial part of the understanding of immunity to COVID-19,” stated Chris Yates, chief government officer of Abingdon Health.

“Mass testing will also help understand what the longevity of immunity is and, in time, help assess the efficiency of any vaccine on the market.  In this respect, high-quality mass antibody,” he added.”


Please enter your comment!
Please enter your name here

fourteen − seven =

Most Popular

AZ’s Tagrisso scores priority review from FDA with EGFR-mutated lung cancer

October 20, 2020: "AstraZeneca’s Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in...

Forxiga recommended for approval in the EU by CHMP for heart failure

October 19, 2020: "AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the...

AstraZeneca advances leadership in renal disease at ASN Kidney Week 2020 Reimagined

October 20, 2020: AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which...

AbbVie’s VENCLEXTA® Receives FDA Approval for Acute Myeloid Leukemia

October 16, 2020: "AbbVie announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination...